Confirmation of visual field abnormalities in the ocular hypertension treatment study

John L Keltner, Chris A. Johnson, Jacqueline M. Quigg, Kimberly E. Cello, Michael A. Kass, Mae O. Gordon

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Objective: To determine the frequency with which visual field abnormalities observed on follow-up visual fields for patients in the Ocular Hypertension Treatment Study were confirmed on retest. Methods: Between April 1, 1994, and March 1, 1999, 21603 visual fields were obtained from 1637 patients in the Ocular Hypertension Treatment Study. When follow-up visual fields are outside the normal limits on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation (P<.05), or both, subsequent follow-up visual fields are monitored to confirm the abnormality. Abnormalities are confirmed if they are again abnormal on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation, or both; if the defect is not artifactual; and if the same index and location are involved. Reliability criteria used by the study consisted of a limit of 33% for false positives, false negatives, and fixation losses. Results: Of the 21603 regular follow-up visual fields, 1006 were follow-up retests performed because of an abnormality (n = 748) or unreliability (n = 258). We found that 703 (94%) of the 748 visual fields were abnormal and reliable, and 45 (6%) were abnormal and unreliable. On retesting, abnormalities were not confirmed for 604 (85.9%) of the 703 originally abnormal and reliable visual fields. Conclusions: Most visual field abnormalities in patients in the Ocular Hypertension Treatment Study were not verified on retest. Confirmation of visual field abnormalities is essential for distinguishing reproducible visual field loss from long-term variability.

Original languageEnglish (US)
Pages (from-to)1187-1194
Number of pages8
JournalArchives of Ophthalmology
Volume118
Issue number9
StatePublished - 2000

Fingerprint

Ocular Hypertension
Visual Fields
Therapeutics
Glaucoma

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Keltner, J. L., Johnson, C. A., Quigg, J. M., Cello, K. E., Kass, M. A., & Gordon, M. O. (2000). Confirmation of visual field abnormalities in the ocular hypertension treatment study. Archives of Ophthalmology, 118(9), 1187-1194.

Confirmation of visual field abnormalities in the ocular hypertension treatment study. / Keltner, John L; Johnson, Chris A.; Quigg, Jacqueline M.; Cello, Kimberly E.; Kass, Michael A.; Gordon, Mae O.

In: Archives of Ophthalmology, Vol. 118, No. 9, 2000, p. 1187-1194.

Research output: Contribution to journalArticle

Keltner, JL, Johnson, CA, Quigg, JM, Cello, KE, Kass, MA & Gordon, MO 2000, 'Confirmation of visual field abnormalities in the ocular hypertension treatment study', Archives of Ophthalmology, vol. 118, no. 9, pp. 1187-1194.
Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO. Confirmation of visual field abnormalities in the ocular hypertension treatment study. Archives of Ophthalmology. 2000;118(9):1187-1194.
Keltner, John L ; Johnson, Chris A. ; Quigg, Jacqueline M. ; Cello, Kimberly E. ; Kass, Michael A. ; Gordon, Mae O. / Confirmation of visual field abnormalities in the ocular hypertension treatment study. In: Archives of Ophthalmology. 2000 ; Vol. 118, No. 9. pp. 1187-1194.
@article{32a9e7b5411b4bc6a86487a9dfd3d7f4,
title = "Confirmation of visual field abnormalities in the ocular hypertension treatment study",
abstract = "Objective: To determine the frequency with which visual field abnormalities observed on follow-up visual fields for patients in the Ocular Hypertension Treatment Study were confirmed on retest. Methods: Between April 1, 1994, and March 1, 1999, 21603 visual fields were obtained from 1637 patients in the Ocular Hypertension Treatment Study. When follow-up visual fields are outside the normal limits on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation (P<.05), or both, subsequent follow-up visual fields are monitored to confirm the abnormality. Abnormalities are confirmed if they are again abnormal on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation, or both; if the defect is not artifactual; and if the same index and location are involved. Reliability criteria used by the study consisted of a limit of 33{\%} for false positives, false negatives, and fixation losses. Results: Of the 21603 regular follow-up visual fields, 1006 were follow-up retests performed because of an abnormality (n = 748) or unreliability (n = 258). We found that 703 (94{\%}) of the 748 visual fields were abnormal and reliable, and 45 (6{\%}) were abnormal and unreliable. On retesting, abnormalities were not confirmed for 604 (85.9{\%}) of the 703 originally abnormal and reliable visual fields. Conclusions: Most visual field abnormalities in patients in the Ocular Hypertension Treatment Study were not verified on retest. Confirmation of visual field abnormalities is essential for distinguishing reproducible visual field loss from long-term variability.",
author = "Keltner, {John L} and Johnson, {Chris A.} and Quigg, {Jacqueline M.} and Cello, {Kimberly E.} and Kass, {Michael A.} and Gordon, {Mae O.}",
year = "2000",
language = "English (US)",
volume = "118",
pages = "1187--1194",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Confirmation of visual field abnormalities in the ocular hypertension treatment study

AU - Keltner, John L

AU - Johnson, Chris A.

AU - Quigg, Jacqueline M.

AU - Cello, Kimberly E.

AU - Kass, Michael A.

AU - Gordon, Mae O.

PY - 2000

Y1 - 2000

N2 - Objective: To determine the frequency with which visual field abnormalities observed on follow-up visual fields for patients in the Ocular Hypertension Treatment Study were confirmed on retest. Methods: Between April 1, 1994, and March 1, 1999, 21603 visual fields were obtained from 1637 patients in the Ocular Hypertension Treatment Study. When follow-up visual fields are outside the normal limits on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation (P<.05), or both, subsequent follow-up visual fields are monitored to confirm the abnormality. Abnormalities are confirmed if they are again abnormal on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation, or both; if the defect is not artifactual; and if the same index and location are involved. Reliability criteria used by the study consisted of a limit of 33% for false positives, false negatives, and fixation losses. Results: Of the 21603 regular follow-up visual fields, 1006 were follow-up retests performed because of an abnormality (n = 748) or unreliability (n = 258). We found that 703 (94%) of the 748 visual fields were abnormal and reliable, and 45 (6%) were abnormal and unreliable. On retesting, abnormalities were not confirmed for 604 (85.9%) of the 703 originally abnormal and reliable visual fields. Conclusions: Most visual field abnormalities in patients in the Ocular Hypertension Treatment Study were not verified on retest. Confirmation of visual field abnormalities is essential for distinguishing reproducible visual field loss from long-term variability.

AB - Objective: To determine the frequency with which visual field abnormalities observed on follow-up visual fields for patients in the Ocular Hypertension Treatment Study were confirmed on retest. Methods: Between April 1, 1994, and March 1, 1999, 21603 visual fields were obtained from 1637 patients in the Ocular Hypertension Treatment Study. When follow-up visual fields are outside the normal limits on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation (P<.05), or both, subsequent follow-up visual fields are monitored to confirm the abnormality. Abnormalities are confirmed if they are again abnormal on the Glaucoma Hemifield Test, the Corrected Pattern Standard Deviation, or both; if the defect is not artifactual; and if the same index and location are involved. Reliability criteria used by the study consisted of a limit of 33% for false positives, false negatives, and fixation losses. Results: Of the 21603 regular follow-up visual fields, 1006 were follow-up retests performed because of an abnormality (n = 748) or unreliability (n = 258). We found that 703 (94%) of the 748 visual fields were abnormal and reliable, and 45 (6%) were abnormal and unreliable. On retesting, abnormalities were not confirmed for 604 (85.9%) of the 703 originally abnormal and reliable visual fields. Conclusions: Most visual field abnormalities in patients in the Ocular Hypertension Treatment Study were not verified on retest. Confirmation of visual field abnormalities is essential for distinguishing reproducible visual field loss from long-term variability.

UR - http://www.scopus.com/inward/record.url?scp=0033822587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033822587&partnerID=8YFLogxK

M3 - Article

C2 - 10980763

AN - SCOPUS:0033822587

VL - 118

SP - 1187

EP - 1194

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 9

ER -